Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial.

Katerina MalagariH MoschourisTh KiakidisS HarwardA KelekisS VrakasD KoundourasD FilipiadisG GlantzounisE EmmanouilA ChatziioannouV VergadisI ElefsiniotisJ KoskinasS DourakisN Kelekis

Published in: Cardiovascular and interventional radiology (2019)

HepaSphere 30-60 μm loaded with doxorubicin provides a safe and effective treatment option for patients with HCC.

Keyphrases

drug delivery
cancer therapy
open label
clinical trial
combination therapy
mass spectrometry
high resolution
replacement therapy
study protocol
placebo controlled